AptarGroup says US antitrust case over nasal spray belongs in New York
MLex Summary: AptarGroup moved to dismiss ARS Pharmaceuticals Operations’ US antitrust case illegally limiting competition to its emergency-use single-dose intranasal spray system, arguing that the issues presented should be determined as part...To view the full article, register now.
Already a subscriber? Click here to view full article